124 related articles for article (PubMed ID: 27086733)
21. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
22. Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.
Kidd JA; Ross P; Buntzman AS; Hess PR
Vet Comp Oncol; 2015 Jun; 13(2):77-88. PubMed ID: 23253146
[TBL] [Abstract][Full Text] [Related]
23. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
24. Massive uric acid crystalluria and cylinduria in a dog after l-asparaginase treatment for lymphoma.
Tvedten H; Lilliehöök I; Rönnberg H; Pelander L
Vet Clin Pathol; 2019 Sep; 48(3):425-428. PubMed ID: 31093999
[TBL] [Abstract][Full Text] [Related]
25. Acute hyperammonemia after L-asparaginase administration in a dog.
Lyles SE; Kow K; Milner RJ; Buckley GJ; Bandt C; Baxter KJ
J Vet Emerg Crit Care (San Antonio); 2011 Dec; 21(6):673-8. PubMed ID: 22316261
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors for treatment of malignant lymphoma in dogs.
Teske E; van Heerde P; Rutteman GR; Kurzman ID; Moore PF; MacEwen EG
J Am Vet Med Assoc; 1994 Dec; 205(12):1722-8. PubMed ID: 7744644
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study.
Feenstra LR; Gehring R; van Geijswijk IM; König T; Prinsen HCMT; Vandemeulebroecke K; Lammens T; Krupa A; Teske E
Vet J; 2022 Aug; 286():105854. PubMed ID: 35781075
[TBL] [Abstract][Full Text] [Related]
29. L-asparaginase for treatment of lymphoid neoplasia in dogs.
Rogers KS
J Am Vet Med Assoc; 1989 Jun; 194(11):1626-30. PubMed ID: 2568982
[No Abstract] [Full Text] [Related]
30. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
[TBL] [Abstract][Full Text] [Related]
31. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
32. Effects of L-asparaginase on plasma amino acid profiles and tumor burden in cats with lymphoma.
LeBlanc AK; Cox SK; Kirk CA; Newman SJ; Bartges JW; Legendre AM
J Vet Intern Med; 2007; 21(4):760-3. PubMed ID: 17708396
[TBL] [Abstract][Full Text] [Related]
33. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
34. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
35. Asparaginase-associated pancreatitis in a dog.
Schleis SE; Rizzo SA; Phillips JC; LeBlanc AK
Can Vet J; 2011 Sep; 52(9):1009-12. PubMed ID: 22379203
[TBL] [Abstract][Full Text] [Related]
36. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
[TBL] [Abstract][Full Text] [Related]
37. Antitumor enzyme: polyethylene glycol-modified asparaginase.
Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
[No Abstract] [Full Text] [Related]
38. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.
LeBlanc AK; Atherton M; Bentley RT; Boudreau CE; Burton JH; Curran KM; Dow S; Giuffrida MA; Kellihan HB; Mason NJ; Oblak M; Selmic LE; Selting KA; Singh A; Tjostheim S; Vail DM; Weishaar KM; Berger EP; Rossmeisl JH; Mazcko C
Vet Comp Oncol; 2021 Jun; 19(2):311-352. PubMed ID: 33427378
[TBL] [Abstract][Full Text] [Related]
39. Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin.
Tater G; Eberle N; Hungerbuehler S; Joetzke A; Nolte I; Wess G; Betz D
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(4):261-6. PubMed ID: 22911257
[TBL] [Abstract][Full Text] [Related]
40. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.
Vet Comp Oncol; 2016 Dec; 14(4):417-446. PubMed ID: 28530307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
